ReviewLipids in health and disease2016
Gene polymorphisms associated with non-alcoholic fatty liver disease and coronary artery disease: a concise review.
Review in Lipids in health and disease, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 25 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
25 citing papers in PubMed, 50 citations in OpenAlex.
- Link between Metabolic Dysfunction-Associated Steatotic Liver Disease and Cardiovascular Diseases.Research (Washington, D.C.) · 2026Review
- ODBAE: a high-performance model identifying complex phenotypes in high-dimensional biological datasets.Communications biology · 2025Article
- Article
- Metabolic syndrome and effect of gene polymorphisms: ADIPOQ, AGT, AGTR1, AGTR2, ApoC-III, NR3C1 and GNB3 gene polymorphisms.Molecular biology reports · 2025Article
- Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: A Bidirectional Association Based on Endothelial Dysfunction.International journal of molecular sciences · 2024Review
- Associations ofWorld journal of hepatology · 2024Article
- Shared Genetic Links Between Nonalcoholic Fatty Liver Disease and Coronary Artery Disease.Global heart · 2024Article
- New Insights into the Pathogenesis of Metabolic-Associated Fatty Liver Disease (MAFLD): Gut-Liver-Heart Crosstalk.Nutrients · 2023Review
- Genetic Markers of Insulin Resistance and Atherosclerosis in Type 2 Diabetes Mellitus Patients with Coronary Artery Disease.Metabolites · 2023Review
- The bidirectional impacts of alcohol consumption and MAFLD for progressive fatty liver disease.Therapeutic advances in endocrinology and metabolism · 2023Review
- New Insights into Non-Alcoholic Fatty Liver Disease and Coronary Artery Disease: The Liver-Heart Axis.Life (Basel, Switzerland) · 2022Review
- Pathophysiological mechanisms of cardiovascular disorders in non-alcoholic fatty liver disease.Gastroenterology and hepatology from bed to bench · 2022Review
- Risk of premature coronary atherosclerosis in patients with nonalcoholic fatty liver disease.Revista da Associacao Medica Brasileira (1992) · 2022Article
- NAFLD and Cardiovascular Diseases: Epidemiological, Mechanistic and Therapeutic Considerations.Journal of clinical medicine · 2021Review
- Genetic Regulatory Networks of Apolipoproteins and Associated Medical Risks.Frontiers in cardiovascular medicine · 2021Review
- Association of TCF7L2 rs7903146 Gene Polymorphism with the Risk of NAFLD and CAD in the Chinese Han Population.Journal of clinical and translational hepatology · 2020Article
- Roles of Adipokines in Digestive Diseases: Markers of Inflammation, Metabolic Alteration and Disease Progression.International journal of molecular sciences · 2020Review
- Assessment of Genetic Aspects of Non-alcoholic Fatty Liver and Premature Cardiovascular Events.Middle East journal of digestive diseases · 2020Review
- Non-alcoholic Fatty Liver Disease and Its Links with Inflammation and Atherosclerosis.Current atherosclerosis reports · 2020Review
- TRIB1 rs17321515 gene polymorphism increases the risk of coronary heart disease in general population and non-alcoholic fatty liver disease patients in Chinese Han population.Lipids in health and disease · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors at 3 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
Non-alcoholic fatty liver disease (NAFLD) is a common chronic liver disease which represents a wide spectrum of hepatic damage. Several studies have reported that NAFLD is a strong independent risk factor for coronary artery disease (CAD). And patients with NAFLD are at higher risk and suggested undergoperiodic cardiovascular risk assessment. Cardiovascular disease (CVD) is responsible for the main cause of death in patients with NAFLD, and is mostly influenced by genetic factors. Both NAFLD and CAD are heterogeneous disease. Common pathways involved in the pathogenesis of NAFLD and CAD includes insulin resistance (IR), atherogenic dyslipidemia, subclinical inflammation, oxidative stress, etc. Genomic characteristics of these two diseases have been widely studied, further research about the association of these two diseases draws attention. The gene polymorphisms of adiponectin-encoding gene (ADIPOQ), leptin receptor (LEPR), apolipoprotein C3 (APOC3), peroxisome proliferator-activated receptors (PPAR), sterol regulatory elementbinding proteins (SREBP), transmembrane 6 superfamily member 2 (TM6SF2), microsomal triglyceride transfer protein (MTTP), tumor necrosis factors-alpha (TNF-α) and manganese superoxide dismutase (MnSOD) have been reported to be related to NAFLD and CAD. In this review, we aimed to provide an overview of recent insights into the genetic basis of NAFLD and CAD.
Indexed as
Identifiers
What Socratic holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.